Miami, Florida – The International Society for Stem Cell Application (ISSCA), a
distinguished division of the Global Stem Cells Group (GSCG), is pleased to unveil a
groundbreaking specialized certification program in Advanced Bio-Stimulation,
encompassing Exosomes, Autologous Fibroblasts, Autologous, and Allogeneic Stem
Cells. The program is scheduled to take place in the beautiful city of Cancun, Mexico, on
May 10th and 11th, 2024, featuring a comprehensive theoretical session on the first day
and hands-on practical training on the second day.
Joining the esteemed faculty is Dr. Andrea Lapeire, a renowned Argentine doctor with
extensive expertise in regenerative medicine and aesthetics. With over eight years of
dedicated service within the ISSCA organization, Dr. Lapeire has been instrumental in
enriching our symposiums and serving as an instructor in certification courses held in
Cancun and Buenos Aires. Dr. Lapeire will spearhead this new program focusing on
autologous fibroblasts and advanced bio-stimulation.
The Advanced Bio-Stimulation program will delve into a myriad of essential topics,
equipping participants with a profound understanding of the latest advancements in
regenerative medicine. Some key areas of focus include:
● Regenerative, Reversive, and Preventive Aesthetic Combination
● Theories of Aging
● Cutaneous Modifications in Aging
● Preventive and Reversive Tools: Differentiation
● Regenerative Therapies and their Importance in Health and Aesthetics
● Definition of Bio-Stimulation
● Mechanical, Physical, and Chemical Bio-Stimulants
● Next Generation of Biological Bio-Stimulants
● Collagenesis
● Local and Systemic Fibroblastic Stimulants
● Physical Stimulants: Various Esthetically Significant Technologies
● Photobiomodulation
● Mechanical Stimulants: Biopuncture, Homeosineathria
● PDO Threads: Fundamentals, Bio-Stimulating Techniques, Combined Technique
Management
● Protocols: Facial and Body● Chemical Stimulants: Skin Booster, Mesotherapy, Next Generation
● Slow-Release Hyaluronic Acid: Combination with Bio-Peptides and Amino Acids
● Biological Stimulants: Homeopathized, Peptides, PRP, and Growth Factors
● Regenerative Effect Stimulants: Exosomes, Autologous Fibroblasts, Autologous
and Allogeneic Stem Cells in Anti-Aging and Pro-Youth Applications
● Technique Differences, Expectations from Each, Choosing the Ideal for Each
Patient, Combining for Result Synergy
● Systemic Stimulants: Orthomolecular, Serum Therapy, Micronutrition,
Homeopathized
The theoretical segment of the program will occur on May 10th, providing participants
with a robust knowledge foundation to leverage during the practical sessions. The
hands-on training will be conducted at the prestigious Cellular Hope Institute facility on
May 11th, enabling participants to apply their theoretical insights in a clinical setting
under the guidance of seasoned instructors.
Benito Novas, Founder of Global Stem Cells Group and Head of Public Relations for the
International Society for Stem Cell Application, expressed his enthusiasm, stating, “We
are thrilled to introduce this innovative course at ISSCA. We are committed to remaining
at the vanguard of medical advancements, offering unparalleled education and training
in regenerative medicine and cell therapies to enable professionals to deliver the utmost
quality care to their patients.”
Participation in these specialized programs is expected to give medical professionals
access to cutting-edge research, technological innovations, and clinical protocols,
ensuring they are aptly equipped to meet the evolving demands of the regenerative
medicine industry. Additionally, ISSCA’s Specializations in Regenerative Medicine and
Cell Therapies provide practitioners with an avenue to elevate their clinical practice and
enhance patient outcomes through advanced, evidence-based therapies.
For registration and further information, please contact:
Email: info@stemcellsgroup.com
Phone: +1305 560 5337
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary
community of scientists and physicians who aspire to treat diseases and lessen human
suffering through advances in science, technology, and the practice of regenerative
medicine. ISSCA serves its members through advancements made in the specialty of
regenerative medicine.
The mission of ISSCA is to establish itself as a global leader in regenerative medicine
certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the
importance of standards and certifications in regenerative medicine as a medical
specialty. To help more people, both locally and globally, as the demand for more
doctors interested in and comfortable with regenerative medicine surges. ISSCA’s
mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell
medicine and research. The company uses its network to bring leadership in
regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to
patients worldwide. The company also partners with policymakers, educators, and
regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol
MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website
www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking
statements include, but are not limited to, statements that express our intentions,
beliefs, expectations, strategies, predictions, or any other information relating to our
future activities or other future events or conditions. These statements are based on
current expectations, estimates, and projections about our business based partly on
assumptions made by management. These statements are not guarantees of future
performance and involve risks, uncertainties, and assumptions that are difficult to
predict. Therefore, actual outcomes and results may and are likely to differ materially
from what is expressed or forecasted in forward-looking statements due to numerous
factors. Any forward-looking statements speak only as of the date of this news release,
and The Global Stem Cells Group undertakes no obligation to update any forward-
looking statement to reflect events or circumstances after the date of this news release.
This press release does not constitute a public offer of any securities for sale. Any
securities offered privately will not be or have not been registered under the Act and
may not be offered or sold in the United States absent registration or an applicable
exemption from registration requirements.
